Olgu Sunumu
BibTex RIS Kaynak Göster

Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report

Yıl 2016, Cilt: 6 Sayı: 1, 32 - 35, 01.03.2016
https://doi.org/10.5799/jmid.328767

Öz

In this paper, we present a 69 years old diabetic patient with mucormycosis who was succesfully treated with liposomal
amphotericin B (LAMB), posaconazole and deferasirox despite having no adequate surgery. There was no relapse on
6 month post-treatment follow-up. We conclude that combination of antifungal antibiotics with deferasirox may be
successful in the salvage therapy of mucormycosis especially in diabetic patients. J Microbiol Infect Dis 2016;6(1): 32-35

Kaynakça

  • 1. Zeka AN, Taşbakan M, Pullukçu H, et al. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013;47:708-716.
  • 2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653.
  • 3. Aslan M, Öz Y, Akay MO, Akşit F. Evaluation of febrile neutropenia in hematologic malignancy patients. Mediterr J Infect Microb Antimicrob 2014; 3:20.
  • 4. Özden M, Denk A, Demirdağ K, Elkıran T. Investigation of Febrile Neutropenic Cases and Risk Factors. Mediterr J Infect Microb Antimicrob 2014;2:3.
  • 5. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infec 2014; 20 Suppl. 3:5-26.
  • 6. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117: 2649-2657.
  • 7. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67:715-722.
  • 8. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125: 375-378.
  • 9. Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65:296-302.
Yıl 2016, Cilt: 6 Sayı: 1, 32 - 35, 01.03.2016
https://doi.org/10.5799/jmid.328767

Öz

Kaynakça

  • 1. Zeka AN, Taşbakan M, Pullukçu H, et al. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013;47:708-716.
  • 2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653.
  • 3. Aslan M, Öz Y, Akay MO, Akşit F. Evaluation of febrile neutropenia in hematologic malignancy patients. Mediterr J Infect Microb Antimicrob 2014; 3:20.
  • 4. Özden M, Denk A, Demirdağ K, Elkıran T. Investigation of Febrile Neutropenic Cases and Risk Factors. Mediterr J Infect Microb Antimicrob 2014;2:3.
  • 5. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infec 2014; 20 Suppl. 3:5-26.
  • 6. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117: 2649-2657.
  • 7. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67:715-722.
  • 8. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125: 375-378.
  • 9. Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65:296-302.
Toplam 9 adet kaynakça vardır.

Ayrıntılar

Konular Sağlık Kurumları Yönetimi
Bölüm Olgu Sunumu
Yazarlar

Uğur Önal Bu kişi benim

Yayımlanma Tarihi 1 Mart 2016
Yayımlandığı Sayı Yıl 2016 Cilt: 6 Sayı: 1

Kaynak Göster

APA Önal, U. (2016). Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. Journal of Microbiology and Infectious Diseases, 6(1), 32-35. https://doi.org/10.5799/jmid.328767
AMA Önal U. Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. J Microbil Infect Dis. Mart 2016;6(1):32-35. doi:10.5799/jmid.328767
Chicago Önal, Uğur. “Treatment of Mucormycosis With Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”. Journal of Microbiology and Infectious Diseases 6, sy. 1 (Mart 2016): 32-35. https://doi.org/10.5799/jmid.328767.
EndNote Önal U (01 Mart 2016) Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. Journal of Microbiology and Infectious Diseases 6 1 32–35.
IEEE U. Önal, “Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”, J Microbil Infect Dis, c. 6, sy. 1, ss. 32–35, 2016, doi: 10.5799/jmid.328767.
ISNAD Önal, Uğur. “Treatment of Mucormycosis With Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”. Journal of Microbiology and Infectious Diseases 6/1 (Mart 2016), 32-35. https://doi.org/10.5799/jmid.328767.
JAMA Önal U. Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. J Microbil Infect Dis. 2016;6:32–35.
MLA Önal, Uğur. “Treatment of Mucormycosis With Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”. Journal of Microbiology and Infectious Diseases, c. 6, sy. 1, 2016, ss. 32-35, doi:10.5799/jmid.328767.
Vancouver Önal U. Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. J Microbil Infect Dis. 2016;6(1):32-5.